3rd Pavia international symposium on advanced kidney cancer

Camillo Porta, Sergio Bracarda

Research output: Contribution to journalArticle

Abstract

Kidney cancers' natural history has radically changed in the past few years, due to the development of novel targeted agents. Despite these improvements, several unanswered questions still remain on the table, regarding the best first-line treatment, the ideal sequence of treatments, the management of specific subgroups of patients (e.g., elderly patients or those with comorbidities) and the relevance of prognostic factors, among many others. To foster discussions among clinicians and investigators working in this field, and to exchange different viewpoints concerning the newest advances in kidney cancer pathogenesis and treatment, the 3rd Pavia International Symposium on Advanced Kidney cancer was held in Pavia (Italy) between 30 June and 1 July 2011. The aim of this report is to summarize the most significant advances in the different disciplines applied to advanced kidney cancer, which were presented and discussed during the meeting, and how these advances will be changing the perspective of patients with this disease.

Original languageEnglish
Pages (from-to)445-453
Number of pages9
JournalExpert Opinion on Pharmacotherapy
Volume13
Issue number3
DOIs
Publication statusPublished - Feb 2012

Fingerprint

Kidney Neoplasms
Natural History
Italy
Comorbidity
Therapeutics
Research Personnel

Keywords

  • Kidney cancer
  • Prognostic factors
  • Targeted agents
  • Therapeutics

ASJC Scopus subject areas

  • Pharmacology (medical)
  • Pharmacology

Cite this

3rd Pavia international symposium on advanced kidney cancer. / Porta, Camillo; Bracarda, Sergio.

In: Expert Opinion on Pharmacotherapy, Vol. 13, No. 3, 02.2012, p. 445-453.

Research output: Contribution to journalArticle

Porta, Camillo ; Bracarda, Sergio. / 3rd Pavia international symposium on advanced kidney cancer. In: Expert Opinion on Pharmacotherapy. 2012 ; Vol. 13, No. 3. pp. 445-453.
@article{c4b0f406c3e74579b1de868d27dc93d2,
title = "3rd Pavia international symposium on advanced kidney cancer",
abstract = "Kidney cancers' natural history has radically changed in the past few years, due to the development of novel targeted agents. Despite these improvements, several unanswered questions still remain on the table, regarding the best first-line treatment, the ideal sequence of treatments, the management of specific subgroups of patients (e.g., elderly patients or those with comorbidities) and the relevance of prognostic factors, among many others. To foster discussions among clinicians and investigators working in this field, and to exchange different viewpoints concerning the newest advances in kidney cancer pathogenesis and treatment, the 3rd Pavia International Symposium on Advanced Kidney cancer was held in Pavia (Italy) between 30 June and 1 July 2011. The aim of this report is to summarize the most significant advances in the different disciplines applied to advanced kidney cancer, which were presented and discussed during the meeting, and how these advances will be changing the perspective of patients with this disease.",
keywords = "Kidney cancer, Prognostic factors, Targeted agents, Therapeutics",
author = "Camillo Porta and Sergio Bracarda",
year = "2012",
month = "2",
doi = "10.1517/14656566.2012.651461",
language = "English",
volume = "13",
pages = "445--453",
journal = "Expert Opinion on Pharmacotherapy",
issn = "1465-6566",
publisher = "Taylor and Francis Ltd.",
number = "3",

}

TY - JOUR

T1 - 3rd Pavia international symposium on advanced kidney cancer

AU - Porta, Camillo

AU - Bracarda, Sergio

PY - 2012/2

Y1 - 2012/2

N2 - Kidney cancers' natural history has radically changed in the past few years, due to the development of novel targeted agents. Despite these improvements, several unanswered questions still remain on the table, regarding the best first-line treatment, the ideal sequence of treatments, the management of specific subgroups of patients (e.g., elderly patients or those with comorbidities) and the relevance of prognostic factors, among many others. To foster discussions among clinicians and investigators working in this field, and to exchange different viewpoints concerning the newest advances in kidney cancer pathogenesis and treatment, the 3rd Pavia International Symposium on Advanced Kidney cancer was held in Pavia (Italy) between 30 June and 1 July 2011. The aim of this report is to summarize the most significant advances in the different disciplines applied to advanced kidney cancer, which were presented and discussed during the meeting, and how these advances will be changing the perspective of patients with this disease.

AB - Kidney cancers' natural history has radically changed in the past few years, due to the development of novel targeted agents. Despite these improvements, several unanswered questions still remain on the table, regarding the best first-line treatment, the ideal sequence of treatments, the management of specific subgroups of patients (e.g., elderly patients or those with comorbidities) and the relevance of prognostic factors, among many others. To foster discussions among clinicians and investigators working in this field, and to exchange different viewpoints concerning the newest advances in kidney cancer pathogenesis and treatment, the 3rd Pavia International Symposium on Advanced Kidney cancer was held in Pavia (Italy) between 30 June and 1 July 2011. The aim of this report is to summarize the most significant advances in the different disciplines applied to advanced kidney cancer, which were presented and discussed during the meeting, and how these advances will be changing the perspective of patients with this disease.

KW - Kidney cancer

KW - Prognostic factors

KW - Targeted agents

KW - Therapeutics

UR - http://www.scopus.com/inward/record.url?scp=84856248002&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=84856248002&partnerID=8YFLogxK

U2 - 10.1517/14656566.2012.651461

DO - 10.1517/14656566.2012.651461

M3 - Article

C2 - 22263875

AN - SCOPUS:84856248002

VL - 13

SP - 445

EP - 453

JO - Expert Opinion on Pharmacotherapy

JF - Expert Opinion on Pharmacotherapy

SN - 1465-6566

IS - 3

ER -